U.S. Medicare advisory panel skeptical of brain-plaque scans
Jan 30 (Reuters) - A Medicare advisory panel on Wednesday expressed skepticism that brain scans using radioactive imaging agents can affect health outcomes of people with early symptoms of memory and cognitive problems.
The medical panel's lack of confidence could deter reimbursement for Eli Lilly's recently approved Amyvid, an imaging agent used to detect levels in the brain of plaque made from beta amyloid protein. The plaque is considered by many researchers to be a hallmark of Alzheimer's disease. (Reporting By Ransdell Pierson; Editing by Tim Dobbyn)
- Islamic State executes soldiers, takes hostages at Syria base: social media |
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |
- Gaza truce holding but Israel's Netanyahu under fire at home |
- WHO shuts Sierra Leone lab after worker infected with Ebola
- Ukraine warns Europe of Russian gas cut-off, Moscow denies